Change in Preferred Drug List Status for "Immunosuppressives, Oral" Drug Class Takes Effect Feb. 12, 2024

The manufacturer of brand name Rapamune products confirmed their products will be discontinued on Dec. 31, 2023, and some supplies of the products will remain available until early 2024. Due to this discontinuation HHSC will remove the non-preferred status from the generic sirolimus products on the preferred drug list (PDL). The preferred status of brand name Rapamune products will not change. This will allow existing stock of these medications to be used.

HHSC will remove the non-preferred status for the following drugs, effective Feb. 12. These changes will allow providers to prescribe the generic sirolimus products without requiring a PDL prior authorization and continue accessing necessary medication for clients.